Excellent chat with many thought provoking comments.
Hosted ably by Gates and Matt Graham-Brown
Moments by NSMC intern, Nimra Sarfaraz
This week, we will discuss the MENTOR trial, which pitted rituximab versus cyclosporine for membranous nephropathy
This week, we will discuss an RCT, a pediatric RCT, and a pediatric RCT in childhood nephrotic syndrome! A trial that asks a question of burning importance to the management of childhood nephrotic syndrome. Join us as we tackle PREDNOS.
Atrosentan makes a return visit to NephJC, but now it goes beyond changes in proteinuria and shows improved kidney outcomes. Is it enough to overcome the fluid complications?
This week, we will discuss a risk score which helps to prognosticate the most common glomerular disease. Not only is IgA most common - it is quite heterogeneous, which makes the problem of who should get treated quite difficult.
They always said not to correct hypernatremia faster than 0.5 mmol/L/hour but what do they know and who are they anyways? New data questions this ancient dogma.
We missed posting the wrap up on this one!
Here are the transcripts
We had two good chats in the shadow of the impending Holiday vacation. Here are the summaries:
We had some great discussion about the trial - and its applicability. Featured input from vascular surgery, anesthesia - and first author Emma Aitken!
Resistant hypertension is an important clinical problem. It is commonly defined as inadequate blood pressure control despite use of three antihypertensive agents of different classes at optimal dosages; one of the three should be an appropriately dosed diuretic. About 10-15% of hypertensive patients have resistant hypertension.
The magical powers of aldosterone antagonists first started to be publicized in the late 90's and in 2003 Calhoun showed a dramatic effect among patients with resistant hypertension:
This was backed up by additional observational data as part of the ASCOT trial experience. The investigators found dramatic efficacy from modest doses of spironolactone among the 1,411 patients that received spironolactone as a fourth line agent:
The first randomized, placebo controlled trial in resistant hypertension was published in 2011. The ASPIRANT trial (PDF) showed a more modest, but still clinically significant reduction blood pressure.
An important caution when looking at spironolactone data is that it appears that black patients are more sensitive to increases in aldosterone, so one could predict more modest blood pressure improvements with spironolactone in a European population. See Tu et al. (Full text).
Another critical aspect of resistant hypertension is addressing non-adherence.
This is why PATHWAY-2's attempt to measure minimize non-adherence is so important.
This week's chat on PATHWAY-2 represents the first randomized controlled trial against an active control group. The fact that aldosterone rises above other fourth line agents to provide meaningful advantages in the treatment of resistant hypertension is important.
We are coming to a new age in hypertension management. On November 9, at 2:00 PM at the AHA meeting in Orlando the SPRINT Trial results will be released. This will almost certainly result in a wave of more aggressive blood pressure control. Almost simultaneously we now have access to the first of the next generation potassium binders, patiromer. This brings the hope of avoiding the most frightening of the side effects from aldosterone antagonists, hyperkalemia. These three seemingly unrelated events are going to be major influences on the treatment of hypertension going forward.